. "Psychiat\u0159i by m\u011Bli pravideln\u011B sledovat t\u011Blesn\u00E9 zdrav\u00ED sv\u00FDch pacient\u016F, proto\u017Ee jsou v mnoha p\u0159\u00EDpadech jedin\u00FDmi l\u00E9ka\u0159i,kter\u00E9 nemocn\u00ED s psychotickou poruchou nav\u0161t\u011Bvuj\u00ED. Z klin. hlediska je t\u0159eba u nemocn\u00FDch l\u00E9\u010Den\u00FDch antipsyhotiky monitorovat metabolick\u00E9, kardiovaskul\u00E1rn\u00ED, neurologick\u00E9 a endokrinn\u00ED poruchy. Rozv\u00EDjen\u00ED spolupr\u00E1ce psychiatra s prakt. l\u00E9ka\u0159i, diabetology a kardiology podporuje pot\u0159ebnou medic\u00EDnskou p\u00E9\u010Di o nemocn\u00E9. U nemocn\u00FDch l\u00E9\u010Den\u00FDch antipsychotiky s vadou zraku by m\u011Bly b\u00FDt prov\u00E1d\u011Bny pravideln\u00E9 oftalmologick\u00E9 kontroly. Pravideln\u00E9 sledov\u00E1n\u00ED t\u011Blesn\u00E9ho zdrav\u00ED nemocn\u00FDch se schizofreni\u00ED zvy\u0161uje bezpe\u010Dnost a sn\u00E1\u0161enlivost antipsychotick\u00E9 medikace a sni\u017Euje morbiditu a mortalitu." . "Sledov\u00E1n\u00ED bezpe\u010Dnosti p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B antipsychotiky"@cs . . "Psychiat\u0159i by m\u011Bli pravideln\u011B sledovat t\u011Blesn\u00E9 zdrav\u00ED sv\u00FDch pacient\u016F, proto\u017Ee jsou v mnoha p\u0159\u00EDpadech jedin\u00FDmi l\u00E9ka\u0159i,kter\u00E9 nemocn\u00ED s psychotickou poruchou nav\u0161t\u011Bvuj\u00ED. Z klin. hlediska je t\u0159eba u nemocn\u00FDch l\u00E9\u010Den\u00FDch antipsyhotiky monitorovat metabolick\u00E9, kardiovaskul\u00E1rn\u00ED, neurologick\u00E9 a endokrinn\u00ED poruchy. Rozv\u00EDjen\u00ED spolupr\u00E1ce psychiatra s prakt. l\u00E9ka\u0159i, diabetology a kardiology podporuje pot\u0159ebnou medic\u00EDnskou p\u00E9\u010Di o nemocn\u00E9. U nemocn\u00FDch l\u00E9\u010Den\u00FDch antipsychotiky s vadou zraku by m\u011Bly b\u00FDt prov\u00E1d\u011Bny pravideln\u00E9 oftalmologick\u00E9 kontroly. Pravideln\u00E9 sledov\u00E1n\u00ED t\u011Blesn\u00E9ho zdrav\u00ED nemocn\u00FDch se schizofreni\u00ED zvy\u0161uje bezpe\u010Dnost a sn\u00E1\u0161enlivost antipsychotick\u00E9 medikace a sni\u017Euje morbiditu a mortalitu."@cs . "10" . "Safety Assessment in Long-Term Treatment with Antipsychotics"@en . "499708" . "T\u016Fma, Ivan" . . "Psychiatrie" . "schizofrenia; antipsychotics; long-term therapy; side effects"@en . "Z(MSM0021620816)" . "6"^^ . "[AE825E515496]" . . . . "Sledov\u00E1n\u00ED bezpe\u010Dnosti p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B antipsychotiky"@cs . . . "11150" . . "226;231" . "Sledov\u00E1n\u00ED bezpe\u010Dnosti p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B antipsychotiky" . "Masopust, Ji\u0159\u00ED" . . "Safety Assessment in Long-Term Treatment with Antipsychotics"@en . "RIV/00216208:11150/06:00004095" . . . "2"^^ . . "CZ - \u010Cesk\u00E1 republika" . "Psychiatrists should provide regular physical health monitoring their patients because in most cases they are the only physicians visited by the psychotic patients. There is a clincal need to monitor antipsychotic-treated patients for metabolic, cardiovascular, neurological and endocrine disturbance and to develop collaborations with primary care physicians, diabetes specialists, and cardiologists to facilitate appropriate medical care for these patients. Antipsychotic-treated patients shoudl also receive regular visual examinations. The monitoring of physical health of patients with schizophrenia increases safety and tolerability of antipsychotics treatment and decreases morbidity and mortality."@en . . "2"^^ . "RIV/00216208:11150/06:00004095!RIV07-MSM-11150___" . "4" . . "Sledov\u00E1n\u00ED bezpe\u010Dnosti p\u0159i dlouhodob\u00E9 l\u00E9\u010Db\u011B antipsychotiky" . . "1211-7579" . .